Inquired if capex hesitancy headwinds were behind them and how the Genentech partnership changes future strategy.

Management confirmed stabilization in instrument and processing assembly demand, with headwinds largely behind them. The Genentech partnership establishes a complementary enterprise-level model for large pharma, alongside existing SPLs for biotechs, allowing earlier monetization and broader engagement. “So we see stabilization, both on the instrument side and on the processing assembly side as well, PAs. We feel the headwinds that we had last year are behind us.”

Asked how the Genentech deal affects discussions with other large SPL customers and what's driving academic traction given funding challenges.

The Genentech deal hasn't changed conversations with existing SPL partners, as it's a distinct multi-platform model for large pharma. Academic traction is primarily from academic institutions pursuing clinical trials (GMP-based), aligning with MaxCyte's strategy to engage researchers earlier for future SPLs. “It hasn't changed the tenure of the conversation with any of the current SPL future partners in the funnel.”

Inquired about the inorganic deal pipeline given the cash balance and changes in the competitive landscape.

MaxCyte prioritizes organic growth, selective M&A, and returning value to shareholders (e.g., share buyback). They have not seen changes in the competitive environment, asserting their platform is best-in-class and displacing competitors. “We have not seen changes in the competitive environment. In fact, with the recent transaction that we announced right now, we displaced a competitor in the clinic.”

MXCT

MaxCyte (MXCT) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 12, 2026

Source: earnings call transcript

Executive summary

MaxCyte Q2 FY26 — Genentech Partnership and Return to Growth

MaxCyte reported Q2 FY26 results ahead of expectations, demonstrating revenue stabilization and sequential growth driven by instrument placements. The company secured a significant multi-platform partnership with Genentech, marking an evolution in its commercial strategy to include enterprise-level agreements alongside traditional SPLs. Despite year-over-year revenue declines and gross margin pressure from product mix, disciplined cost management and share repurchases underscore a focus on financial health, with management confident in a return to revenue growth in the second half of the year.

Highlights

Total revenue of $7.3 million was ahead of expectations, reflecting stabilization.
Achieved sequential revenue growth in Q2 compared to Q1, primarily driven by instrument placements.
Delivered a meaningful reduction in net loss year-over-year, with operating expenses decreasing 25% to $15.8 million.
Announced a multi-platform technology license partnership with Genentech, establishing an enterprise-level commercial framework.
Repurchased approximately $5.5 million of stock from a $10 million authorization, demonstrating capital return.

Concerns

Total revenue decreased 15% year-over-year to $7.3 million.
Core revenue decreased 21% year-over-year to $6.5 million, impacted by discontinued partner programs.
Gross margin declined to 77% in Q2 FY26 from 82% in Q2 FY25, primarily due to product mix with higher instrument revenue.

Guidance & targets

Category	Target	Timeline	Confidence
Total Revenue	$30 million to $32 million high materiality	FY26	High
Core Revenue	$25 million to $27 million medium materiality	FY26	High
SPL Milestones and Royalties Revenue	$5 million medium materiality	FY26	High
Total Revenue Growth	low single-digit year-over-year growth medium materiality	H2 2026 · FY26	High
SPL Milestone Revenue	$3 million medium materiality	FY26	High
SPL Royalty Revenue	$2 million medium materiality	FY26	High
Cash, Cash Equivalents, and Investments	at least $130.5 million high materiality	End of FY26	High

Deals & partnerships

Genentech Multi-platform technology license partnership providing access to Expert DTX platform and additional platform technologies (electroporation and analytical assessment capabilities) across research, clinical development, and manufacturing workflows.

Enterprise-level relationship supporting multiple cell therapy programs, shifting value capture earlier in the customer life cycle.

Risks & headwinds

Inventory drawdown by largest customer first half of 2026

significant portion now behind us

Mitigation:largely subsided, stable processing assembly demand expected

Discontinuation of partner clinical programs last year, impacting H1 2026

impacted license revenue

Mitigation:largely subsided, stable license revenue expected

Product mix impact on gross margin Q2 FY26, expected to continue in back half of year

Gross margin was 77% in Q2 FY26 compared to 82% in Q2 FY25

Mitigation:expect gross margins in the mid-70s

Cell therapy funding environment not as robust as broader biotech or 2020/2021 levels ongoing

not a return back to your 2020, 2021 years

Mitigation:diversifying revenue model, launching new products, working with large pharma, leaning into the space without needing prior funding levels

What to watch in Q3 FY26

Return to year-over-year revenue growth

H2 2026

Current Q2 FY26 total revenue decreased 15% YoY; core revenue decreased 21% YoY

Target low single-digit year-over-year revenue growth

Why it matters

Management's key objective for the year is to return to growth in the second half, signaling market stabilization and execution.

Our objective was clear, stabilize revenue in the first half and return to growth in the second half. results reflects the stabilization where both our Q1 and Q2 revenues were ahead of our expectations and we remain confident in our ability to achieve our goal of returning to growth in the back half of the year.

Find out whether MXCT delivers this. Inve re-checks your case every morning.

Q&A highlights

Asked for details on the source of instrument revenue growth and clarification on why non-core revenue guidance wasn't raised given strong Casgevy performance.

Instrument revenue growth was broad-based across research, process development, and clinical, with early DTX traction. Management acknowledged Casgevy's strong performance but maintained royalty guidance due to potential quarter-to-quarter variability and a policy of not commenting on partner programs.

“The instrument side, Julie was across the board. We saw it in research, process development, and clinical as well.”

asked by Julie Simmonds · answered by Maher Masoud

2 min read 5 chapters

Detailed narrative

Strategic Partnership with Genentech

MaxCyte announced a multi-platform technology license partnership with Genentech, marking an evolution in its commercial strategy. This enterprise-level agreement supports multiple cell therapy programs across research, clinical development, and manufacturing, providing durable recurring license and platform access revenue, complemented by milestone-based opportunities. This model aims to shift value capture earlier in the customer life cycle and diversify revenue streams beyond single-program SPLs.

Return to Growth and Operational Discipline

The company achieved sequential revenue growth in Q2 FY26, driven by instrument placements, and remains confident in returning to year-over-year growth in the second half. This stabilization follows headwinds from inventory drawdown and discontinued clinical programs. Disciplined execution led to a meaningful reduction in net loss year-over-year, with operating expenses decreasing by 25% due to prior restructuring efforts.

Instrument Adoption and Platform Expansion

Expert DTX adoption continues to build, showing encouraging early traction in discovery and optimization workflows for both ex vivo and in vivo cell and gene therapy. The DTX platform offers a seamless path to scale for CGMP manufacturing using STX and GTX instruments. Investments in R&D priorities like DTX, SECURE, and strategic collaborations are designed to broaden customer engagement and strengthen long-term growth opportunities.

SPL Portfolio and Commercial Trajectory

MaxCyte maintains 30 total licensed partnerships, including 29 SPL partners. The SPL portfolio remains a key driver of long-term value, with five partner programs potentially launching commercially in the next couple of years. The company continues to see strong commercial trajectory for Casgevy, with Vertex reporting $76 million in Q2 FY26 revenue, reflecting 75% sequential growth, and over 100 patient initiations for the third consecutive quarter.

Market Environment and Competitive Positioning

Management noted a stabilization in the cell therapy funding environment, distinct from the broader biotech funding recovery, and stated they don't require a return to 2020-2021 levels for growth. MaxCyte believes its platform is best-in-class, displacing competitors in both academic and industry settings, and is not seeing new competition.

The company is actively expanding its presence in Asia-Pacific to capitalize on growing cell therapy investments in regions like China, Japan, and Korea.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.